The MSH/ACTH analog ORG 2766 in anxiety disorders.
The anxiolytic effects of the MSH/ACTH analog ORG 2766 were assessed in three different groups of patients with an anxiety disorder: panic disorder, generalized anxiety and social phobia. Patients were treated with capsules containing 20 mg ORG 2766 or placebo and received 4 capsules daily for six weeks. A slight reduction on the Hamilton Anxiety Scale was found after ORG 2766 treatment in the panic disorder patients, while the peptide did not affect the number of panic attacks in these patients. In the other two patient groups no anxiolytic effect of ORG 2766 was observed.
Den Boer
J A
JA
Department of Biological Psychiatry, University Hospital Utrecht, The Netherlands.
Westenberg
H G
HG
De Vries
H
H
D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy*; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D016584:Panic Disorder / Q000188:drug therapy; D010446:Peptide Fragments / Q000627:therapeutic use*; D010698:Phobic Disorders / Q000188:drug therapy; D013997:Time Factors
D000927:Anticonvulsants; D010446:Peptide Fragments; C013765:Org 2766; D000324:Adrenocorticotropic Hormone